SCHEMBL6806952

SCHEMBL6806952

Fc1cccc(C2(c3cccc(F)c3)C=Cc3c(-c4ccccc4)n[nH]c3C2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 4/20 0.40
HTR7 P34969 2/20 0.40
LMNA P02545 1/20 0.35
MAPK10 P53779 1/20 0.35
ALPL P05186 1/20 0.34
NOTUM Q6P988 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
MAP2K7 O14733 1/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32
OPRK1 P41145 1/20 0.32
OPRL1 P41146 1/20 0.32
BACE1 P56817 1/20 0.32
MAOB P27338 1/20 0.32
USP7 Q93009 1/20 0.32
KDM1A O60341 2/20 0.31
ADORA2A P29274 1/20 0.31
ADORA2B P29275 1/20 0.31
ADORA1 P30542 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795936 0.99 HTR7 (0.39) MAP2K4HTR7LMNAMAPK10ALPL
SCHEMBL6800268 0.92 MAPK14 (0.36) MAP2K4HTR7ALPL
SCHEMBL6807007 0.91 HTR7 (0.36) HTR7ALPLBACE1
SCHEMBL6802466 0.90 ALPL (0.41) MAP2K4HTR7ALPLMAP2K7BACE1
SCHEMBL6801041 0.88 MAP2K4 (0.39) MAP2K4HTR7LMNAMAPK10ALPL
SCHEMBL6806613 0.88 ALPL (0.43) MAP2K4HTR7ALPLMAP2K7BACE1
SCHEMBL5876594 0.87 MAPK10 (0.42) MAP2K4HTR7LMNAMAPK10ALPL
SCHEMBL5876664 0.87 HTR7 (0.33) MAP2K4HTR7ADORA2A
SCHEMBL6794844 0.86 MAP2K4 (0.40) MAP2K4HTR7LMNAMAPK10ALPL
SCHEMBL6799788 0.86 LMNA (0.34) MAP2K4HTR7LMNAMAPK10USP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT MAP2K4 3422/4885HTR7 211/4885LMNA 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.